The Board of Directors has general responsibility for Nightingale’s governance and the appropriate organisation of operations. The Board of Directors has approved rules of procedure that define the matters within the Board of Directors’ responsibility. The Board of Directors affirms the principles of Nightingale’s strategy, organisation, accounting and controlling the management of assets, and appoints the CEO. The CEO is responsible for carrying out the strategy of Nightingale and for day-to-day administration based on the instructions and orders issued by the Board of Directors.
The company’s Board of Directors consists of minimum of 3 and maximum of 10 ordinary members. The term of office of the members of the Board of Directors expires at the end of the first Annual General Meeting of Shareholders following their election. The Board of Directors elects a Chairman from among its members for the duration of its term of office.
In addition to the governing bodies of Nightingale, the company has established a Scientific Advisory Board. The Scientific Advisory Board is not a decision-making body but acts in a supporting role to advance Nightingale’s strategy to translate novel scientific findings from flagship biobanks and research cohorts to preventive health applications available for individuals globally. Nightingale’s Scientific Director acts as the Chairman of the Scientific Advisory Board.
Members of the scientific advisory board are:
Prof. George Davey Smith
University of Bristol, UK
Prof. John Danesh
University of Cambridge, UK
Prof. Eline Slagboom
Leiden University, Netherlands
Prof José Ordovás
Tufts University, USA